July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Efficacy and tolerability of a new thermostable formulation of latanoprost in nanoparticles
Author Affiliations & Notes
  • Lourdes Rodriguez
    Laboratorios Poen , Buenos Aires, Buenos Aires, Argentina
  • Javier Fernando Casiraghi
    Hospital de Clínicas Jose de San Martín, Buenos Aires, Argentina
  • Daniel Grigera
    Hospital Santa Lucía, Buenos Aires, Argentina
  • Alejo Peyret
    Hospital Durand , Buenos Aires, Argentina
  • Silvia Passerini
    Laboratorios Poen , Buenos Aires, Buenos Aires, Argentina
  • Footnotes
    Commercial Relationships   Lourdes Rodriguez, Laboratorios Poen (E); Javier Casiraghi, Laboratorios Poen (C); Daniel Grigera, Laboratorios Poen (C); Alejo Peyret, Laboratorios Poen (C); Silvia Passerini, Laboratorios Poen (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1236. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lourdes Rodriguez, Javier Fernando Casiraghi, Daniel Grigera, Alejo Peyret, Silvia Passerini; Efficacy and tolerability of a new thermostable formulation of latanoprost in nanoparticles. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1236.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Benzalkonium chloride (BAK) has known toxic effects on the ocular surface on long-term use. A new latanoprost 0.005% BAK-free ophthalmic nanoemulsion (LNe) was developed to improve patient comfort and tolerability. It is stable at 30°C and 35% relative humidity for 24 months. We hypothesized that this innovative formulation has the same intraocular pressure (IOP)-lowering efficacy and is better tolerated than the BAK-containing latanoprost solution (LSc).

Methods : A prospective, open-label, single-arm, 12-week study was carried on. Patients over 18 years old with primary open-angle glaucoma under treatment with LSc for ≥ 6 months (baseline), switched to LNe once daily. As primary outcome, IOP-lowering efficacy was evaluated after 4, 8 and 12 weeks of treatment with LNe. Non inferiority was defined as a mean difference (95% CI) from baseline of <1.5 mm Hg at every timepoint after switching. As secondary outcome, ocular surface damage was determined using Ocular Surface Disease Index (OSDI) score, Schirmer I Test, Break-up time (BUT), conjunctival hyperemia and corneal staining at baseline and after 4, 8 and 12 weeks of treatment with LNe. Adverse events were reported. Two-tailed repeated measures ANOVA with Bonferroni correction was used, and significance was set at p < 0.05.

Results : A total of 103 patients (198 eyes) concluded the study. Six patients discontinued because of ocular itching, increased tearing, blurred vision, strange body sensation, dry eye or allergic eye reactions. No serious treatment-related adverse effects were reported. No patient had IOP > 20 mm Hg. LNe was non-inferior in lowering IOP than LSc, as 95% CI of mean IOP at every timepoint after switch to LNe were within the 1.5 mm Hg non-inferiority margin from baseline IOP (13.13-16.13 mm Hg): 13.65-14.35, 13.38-14.07, 13.33-13.98 mm Hg (4, 8 and 12 weeks, respectively) (figure 1). After 12 weeks of treatment with LNe, all ocular surface parameters improved (table 1). Number of eyes with conjunctival hyperemia and corneal staining decreased 27.7% and 19.2%, respectively.

Conclusions : The new formulation of latanoprost in nanoemulsion showed the same IOP-lowering efficacy as the conventional formulation with significant improvements of ocular surface parameters, adding the advantage of being stored at room temperature.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×